7 histone deacetylase inhibitor IEM 1754 Techniques Revealed

Much like danshensu, both with the ions at m/z 137 of histone deacetylase inhibitor protocatechuic aldehyde and m/z 153 of protocatechuic acid developed the identical ion at m/z 109 corresponding towards the loss of CO and CO2, respectively.

Other two fragment ions, ion at m/z 321 and ion at m/z 339 corresponding towards the loss with the second danshensu along with the rst caffeic acid. These data are constant with these in the literature. For that reason, peak 10 was tentatively identied as salvianolic acid B. Similarly, histone deacetylase inhibitor peaks 9, 14 were identied as rosmarinic acid and salvianolic acid A separately. Rhizoma Coptids alkaloids, which were the most abundant constituents in the alcohol extra of FTZ, exhibited a special fragmentation pathway in the positive ion mode. It is well known that loss the neutral species such as CO, CH3, CH4 and CH2O were observed in the MS2 spectra of Rhizoma Coptids alkaloids.

In addition to Rhizoma Coptids alkaloids in positive ion IEM 1754 mode, three diterpenoids also exhibited ions in positive ion mode. It is well known that hydrogen at C 1 and oxygen at C 11 of tanshinones were the source of the dissociated H2O and the neutral species such as CO, H2O, C2H5 and C3H6 were also observed in the MS2 spectra. Peak 45 showed a molecular ion at m/z 297 in MS spectra, and exhibited an ion at m/z 279 in MS2 spectra, which corresponded to three fragment ions at m/z 268 , m/z 227 and m/z 251 , showing the neutral loss of CO, H2O, C2H5 and C3H6 in the fragmentation pathway. According to these data, peak 45 was tentatively identied as cryptotanshinone.

By comparison with literature data, this component was ascertained as coniferin. IEM 1754 By comparison with the mass chromatography of FTZ and the rat serum samples from control group, the MS spectra for rat serum samples from FTZ treated group exhibited 27 peaks in common, which demonstrated that the 27 components from FTZ were absorbed into the rat blood after oral administration.